Cahill Represents Financing Sources in Acquisition of Bausch & Lomb by Valeant Pharmaceuticals

August 6, 2013

Cahill represented the financing sources in each of Valeant’s Common Stock, Bank Loan and High Yield Bond Transactions relating to its acquisition of Bausch & Lomb.

Cahill represented the underwriters in connection with the public offering of 27 million shares of common stock of Valeant Pharmaceuticals International, resulting in gross proceeds of approximately $2.3 billion.  Cahill also represented the initial purchasers in the offering of approximately $3.2 billion aggregate principal amount of senior unsecured notes by Valeant and the lead arrangers in connection with approximately $4.0 billion of new incremental term loan borrowings for Valeant, all in connection with financing Valeant’s acquisition of Bausch & Lomb.